<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03666832</url>
  </required_header>
  <id_info>
    <org_study_id>2017-10-150</org_study_id>
    <nct_id>NCT03666832</nct_id>
  </id_info>
  <brief_title>Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine and Nab-Paclitaxel</brief_title>
  <acronym>MP-PDAC-01</acronym>
  <official_title>Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine and Nab-Paclitaxel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joon Oh Park</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Inclusion

             1. Subjects who are males or females ≥ 19 years of age

             2. Subjects who have the following history of first-line gemcitabine and
                nab-paclitaxel among patients with cytologically or histologically proven
                metastatic pancreatic ductal adenocarcinoma

             3. Subjects who can give written informed consent for participation in this trial
                after receiving explanations of this trial

             4. Subjects who have the following laboratory test values:

                  -  bilirubin ≤ 1.5 x ULN (upper limit of normal)

                  -  aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 x ULN

                  -  serum creatinine ≤ 1.5 x ULNor estimated creatinine clearance ≥ 40 mL/min
                     (Cockcroft-Gault)

                  -  partial thromboplastin time (aPTT) ≤ 1.5 x ULN

                  -  absolute neutrophil count (ANC) ≥ 1,500 cells/µL

                  -  platelet count ≥ 100,000/µL

                  -  hemoglobin ≥ 9.0 g/dL

             5. Subjects who have at least a 12-week life expectancy at the Investigator's
                discretion

             6. Subjects who have Eastern Cooperative Oncology Group (ECOG)Performance Status 0-1

        -  Exclusion

             1. Subjects who were treated with surgery, radiotherapy, chemotherapy or
                investigational therapy within 2 weeks (note: placement of biliary stent is
                allowed)

             2. Subjects who have uncontrolled CNS metastases (patients who require steroids should
                be on a stable or decreasing dose for at least 2 weeks)

             3. Subjects who have any contraindications for 5-FU, leucovorin, or oxaliplatin

             4. Subjects who have moderate or severe cardiovascular disease

                  -  Subjects who have myocardial infarction, unstable angina pectoris, New York
                     Heart Association (NYHA) Class III/IV congestive heart failure, or
                     uncontrolled hypertension within 6 months before screening

                  -  Subjects who have major abnormalities at the Investigator's discretion based
                     on electrocardiogram (ECG)and Doppler ECHO results at screening or within 14
                     days before screening

                  -  Subjects who have increase in brain natriuretic peptide(BNP) or increase in
                     troponin (over 99th percentile upper reference limit) at Screening (based on
                     the normal range of relevant study center)

                  -  Subjects who have risk factors for ascending aortic aneurysm such as genetic
                     disorder and trauma and risk factors for aortic stenosis

                  -  Subjects who have a history of heart or aorta surgery

             5. Subjects who have clinically significant gastrointestinal bleeding within 4 weeks
                before screening

             6. Subjects who have a known history or suspected hypersensitivity to any excipients
                of the investigational product or combination drug(s)

             7. Subjects who have received prior treatment targeting the signaling pathway of TGF-β

             8. Subjects who have a disease or condition that affects the mechanism of the
                investigational product, or are currently using or planning to use:

                  -  Drugs that are exclusively or primarily eliminated by cytochrome P-450 isozyme
                     (CYP) including CYP1A2, CYP2B6, or CYP3A4

                  -  Drugs that are exclusively or primarily eliminated by UDP
                     glucuronyltransferase (UGT) 1A1 (UGT1A1)

                  -  Drugs that are substrates for the drug transporter multidrug resistance
                     protein 1 (MDR1) have a narrow therapeutic window or are strong inhibitors of
                     drug transporter MDR1

                  -  Drugs that are strong inhibitors or inducers of CYP2D6 or CYP3A4

             9. Subjects who are unable to swallow tablets

            10. Subjects who have a history of or are suspected of drug abuse

            11. Female subjects of child-bearing potential who have a positive result on a
                pregnancy test at screening or are unable to agree to use an effective barrier
                method of birth control to avoid pregnancy during the study period (e.g.,
                sterilization, intrauterine contraceptive device, combination of oral contraception
                and barrier contraception, combination of other hormone delivery systems and
                barrier contraception, contraceptive cream, combination of cream, jelly, or form
                and diaphragm or condom)

            12. Subjects, in the opinion of the Investigator, who are unsuitable to participate in
                the study

            13. Subjects who were treated with other investigational products within 28 days before
                screening or within a period shorter than 5-timesthe half-life of the
                investigational product
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 17, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 14, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pregression free survival</measure>
    <time_frame>up to 6 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Metastatic Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Arm1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TEW-7197 100mg will be administered orally once a day 5days and rest 2days. Study treatment will be continued until objective disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TEW-7197</intervention_name>
    <description>TEW-7197 1cycle 14days
-intake 5days, rest 2days</description>
    <arm_group_label>Arm1</arm_group_label>
    <other_name>TEW-7197, FOLFOX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1) Subjects who are males or females ≥ 19 years of age 2) Subjects who have the
             following history of first-line gemcitabine and nab-paclitaxel among patients with
             cytologically or histologically proven metastatic pancreatic ductal adenocarcinoma 3)
             Subjects who can give written informed consent for participation in this trial after
             receiving explanations of this trial 4) Subjects who have the following laboratory
             test values:

          -  bilirubin ≤ 1.5 x ULN (upper limit of normal)

          -  aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 x ULN

          -  serum creatinine ≤ 1.5 x ULNor estimated creatinine clearance ≥ 40 mL/min
             (Cockcroft-Gault)

          -  partial thromboplastin time (aPTT) ≤ 1.5 x ULN

          -  absolute neutrophil count (ANC) ≥ 1,500 cells/µL

          -  platelet count ≥ 100,000/µL

          -  hemoglobin ≥ 9.0 g/dL 5) Subjects who have at least a 12-week life expectancy at the
             Investigator's discretion 6) Subjects who have Eastern Cooperative Oncology Group
             (ECOG)Performance Status 0-1

        Exclusion Criteria:

          -  1) Subjects who were treated with surgery, radiotherapy, chemotherapy or
             investigational therapy within 2 weeks (note: placement of biliary stent is allowed)
             2) Subjects who have uncontrolled CNS metastases (patients who require steroids should
             be on a stable or decreasing dose for at least 2 weeks) 3) Subjects who have any
             contraindications for 5-FU, leucovorin, or oxaliplatin 4) Subjects who have moderate
             or severe cardiovascular disease

          -  Subjects who have myocardial infarction, unstable angina pectoris, New York Heart
             Association (NYHA) Class III/IV congestive heart failure, or uncontrolled hypertension
             within 6 months before screening

          -  Subjects who have major abnormalities at the Investigator's discretion based on
             electrocardiogram (ECG)and Doppler ECHO results at screening or within 14 days before
             screening

          -  Subjects who have increase in brain natriuretic peptide(BNP) or increase in troponin
             (over 99th percentile upper reference limit) at Screening (based on the normal range
             of relevant study center)

          -  Subjects who have risk factors for ascending aortic aneurysm such as genetic disorder
             and trauma and risk factors for aortic stenosis

          -  Subjects who have a history of heart or aorta surgery 5) Subjects who have clinically
             significant gastrointestinal bleeding within 4 weeks before screening 6) Subjects who
             have a known history or suspected hypersensitivity to any excipients of the
             investigational product or combination drug(s) 7) Subjects who have received prior
             treatment targeting the signaling pathway of TGF-β 8) Subjects who have a disease or
             condition that affects the mechanism of the investigational product, or are currently
             using or planning to use:

          -  Drugs that are exclusively or primarily eliminated by cytochrome P-450 isozyme (CYP)
             including CYP1A2, CYP2B6, or CYP3A4

          -  Drugs that are exclusively or primarily eliminated by UDP glucuronyltransferase (UGT)
             1A1 (UGT1A1)

          -  Drugs that are substrates for the drug transporter multidrug resistance protein 1
             (MDR1) have a narrow therapeutic window or are strong inhibitors of drug transporter
             MDR1

          -  Drugs that are strong inhibitors or inducers of CYP2D6 or CYP3A4 9) Subjects who are
             unable to swallow tablets 10) Subjects who have a history of or are suspected of drug
             abuse 11) Female subjects of child-bearing potential who have a positive result on a
             pregnancy test at screening or are unable to agree to use an effective barrier method
             of birth control to avoid pregnancy during the study period (e.g., sterilization,
             intrauterine contraceptive device, combination of oral contraception and barrier
             contraception, combination of other hormone delivery systems and barrier
             contraception, contraceptive cream, combination of cream, jelly, or form and diaphragm
             or condom) 12) Subjects, in the opinion of the Investigator, who are unsuitable to
             participate in the study 13) Subjects who were treated with other investigational
             products within 28 days before screening or within a period shorter than 5-timesthe
             half-life of the investigational product
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>joonoh park, Ph MD</last_name>
    <phone>82-2-2148-7394</phone>
    <email>oncopark66@skku.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joon Oh Park, M.D., Ph.D</last_name>
      <phone>82 2 3410 3459</phone>
      <email>oncopark@skku.edu</email>
    </contact>
    <contact_backup>
      <last_name>yoon Jeong Ahn</last_name>
      <phone>221487395</phone>
      <phone_ext>82</phone_ext>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>September 10, 2018</study_first_submitted>
  <study_first_submitted_qc>September 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2018</study_first_posted>
  <last_update_submitted>December 26, 2019</last_update_submitted>
  <last_update_submitted_qc>December 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Joon Oh Park</investigator_full_name>
    <investigator_title>Samsung Medical Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

